Healthcare Overbought Stocks: Pernix Therapeutics Holdings (NASDAQ:PTX), AVEO Pharmaceuticals (NASDAQ:AVEO), WellPoint Inc. (NYSE:WLP), Horizon Pharma (NASDAQ:HZNP)

Pernix Therapeutics Holdings Inc. (NASDAQ:PTX) wants to start life with a new slate. It has taken several measures to wipe out the old issues. The company took care of two major worries. Pernix Therapeutics Holdings Inc. (NASDAQ:PTX) stock performance was 10.43% in last session and finished the day at $5.93. Traded volume was 1.14 million shares in the last session and the average volume of the stock remained 438,665.00 shares. The beta of the stock remained 1.37. Pernix Therapeutics Holdings Inc. (NASDAQ:PTX) insider ownership is 8.60%.

On March 18, 2014, AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) entered into Amendment No. 1 to Option and License Agreement with Biogen Idec MA Inc. to that certain Option and License Agreement by and between AVEO and Biogen Idec International GmbH dated March 18, 2009, as assigned to Biogen on or about August 31, 2011, regarding the development and commercialization of AVEO’s discovery-stage ErbB3-targeted antibodies, or AVEO’s AV-203 program, for the potential treatment and diagnosis of cancer and other diseases in humans. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) rose 7.19% to $1.79 Friday on volume of 2.97 million shares. The intra-day range of the stock was $1.71 – $1.88. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) has a market capitalization of 92.28 million.

WellPoint(NYSE:WLP) is already raising a 2014 earnings forecast it laid out earlier this year, but the nation’s second largest health insurer’s projections are still below analyst expectations. WellPoint Inc. (NYSE:WLP)’s stock on March 21, 2014 reported a higher of 0.06% to the closing price of $99.77. Its fifty two weeks range is $63.31 – $102.56. The total market capitalization recorded 30.18 billion. The overall volume in the last trading session was 7.62 million shares. In its share capital, WellPoint Inc. (NYSE:WLP) has 302.45 million outstanding shares.

Deerfield-based Horizon Pharma Inc. (NASDAQ:HZNP) said Wednesday it will move its headquarters to Ireland as part of a reverse merger with Dublin-based Vidara Therapeutics International Inc. valued at $660 million. On Friday, shares of Horizon Pharma Inc. (NASDAQ:HZNP) advanced 3.21% to close the day at $17.35. Company return on investment (ROI) is -47.60% and its monthly performance is recorded as 56.17%. Horizon Pharma Inc. (NASDAQ:HZNP) quarterly revenue growth is 155.90%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone